Abeona Therapeutics Inc

NASDAQ ABEO

Data sourced from

and

Download Data

Abeona Therapeutics Inc Revenue for the quarter ending March 31, 2024: USD 0.00

Abeona Therapeutics Inc Revenue is USD 0.00 for the quarter ending March 31, 2024, a 0.00% change year over year. The revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Abeona Therapeutics Inc Revenue for the quarter ending March 31, 2023 was USD 0.00, a -100.00% change year over year.
Abeona Therapeutics Inc Revenue for the quarter ending March 31, 2022 was USD 346.00 K, a -88.47% change year over year.
Abeona Therapeutics Inc Revenue for the quarter ending March 31, 2021 was USD 3.00 M, a 0.00% change year over year.
Abeona Therapeutics Inc Revenue for the quarter ending March 31, 2020 was USD 0.00, a 100.00% change year over year.

NASDAQ: ABEO

Abeona Therapeutics Inc

CEO	Dr. Vishwas Seshadri M.B.A., Ph.D.
IPO Date	Sept. 19, 1980
Location	United States
Headquarters	1330 Avenue of the Americas, New York, NY, United States, 10019
Employees	84
Sector	Healthcare
Industry	Biotechnology

Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

Key trends